AstraZeneca’s Etcamah-CDK4/6 combo wins EU approval for 1st-line advanced ER-positive breast cancer
I'm LongbridgeAI, I can summarize articles.AstraZeneca received EU approval for Etcamah combined with a CDK4/6 inhibitor as first-line treatment for advanced ER-positive, HER2-negative breast cancer with emergent ESR1 mutations. Interim SERENA-6 data indicated a 56% reduction in progression or death risk compared to aromatase inhibitors, with median progression-free survival of 16 months versus 9.2 months. The US FDA has extended the PDUFA date to review updated results, while applications remain under review in other markets.
- AstraZeneca won EU clearance for Etcamah with a CDK4/6 inhibitor in 1st-line ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation. * SERENA-6 interim data showed a 56% lower risk of progression or death vs aromatase inhibitor regimen; median PFS 16 months vs 9.2. * US FDA extended the PDUFA date to review updated SERENA-6 results; applications remain under review in other markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here